PFFSUMMIT2017

## SUMMIT POSTER PRESENTATIONS

"Metformin ameliorates myofibroblast differentiation: Possible role in idiopathic pulmonary fibrosis"
Name: Abdalla, Maha
Institution: South College, School of Pharmacy

"Single cell RNA-sequencing of thousands of cells from IPF lungs reveals cellular diversity of distinct cellular populations"
Name: Adams, Taylor
Institution: Yale University, School of Medicine

"Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort"
Name: Adegunsoye, Ayodeji
Institution: The University of Chicago

"The Effect of the Soluble Guanylate Cyclase Inducer Bay 41-2272 on Proliferation, Activation, and Apoptosis Resistance in Idiopathic Pulmonary Fibrosis Derived Fibroblasts."
Name: Aljeburry, Bilal
Institution: George Mason University

"Association between Acute Respiratory Disease Events and the MUC5B Promoter Polymorphism in Smokers"
Name: Ash, Samuel
Institution: Brigham and Women's Hospital

"The CATALYST Study: A Clinical Utility Analysis of the BRAVE (Bronchial Sample Collection for A Novel Genomic Test) Registry, using the Envisia Genomic Classifier"
Name: Barth, Neil
Institution: Veracyte inc

"Inhibition of fibrosis with multi-agent therapy in pulmonary fibrosis: Results of a drug library screening."
Name: Batzlaff, Cassandra
Institution: Mayo Clinic

"A retrospective analysis of CAPACITY006 using Quantitative Image Analysis demonstrating the prognostic effect on lung function and detection of changes in fibrosis without FVC decline"
Name: Belloni, Paula
Institution: Genentech, Inc.

"Epigenetic changes in the Promoter regions of Cytochrome P450 2B6 and 3A4 in Idiopathic Pulmonary Fibrosis Fibroblast Derived DNA"
Name: Beuschel, Rebecca
Institution: George Mason University

“ER stress effector CHOP augments AEC apoptosis and worsens lung fibrosis”
Name: Burman, Ankita
Institution: Vanderbilt University

“Clinical characteristics of patients with advanced idiopathic pulmonary fibrosis (IPF)”
Name: De Andrade, Joao
Institution: The University of Alabama at Birmingham

“Delivery of IL-10 using a Novel High Molecular Weight Hyaluronan Vehicle Reduces Lung Fibrosis in a Bleomycin Mouse Model of Lung Injury”
Name: De Jesus Perez, Vinicio
Institution: Stanford University

“Caregiver Support Group Meetings as a Resource for Pulmonary Fibrosis Caregivers”
Name: Dimmock, Anne
Institution: The Pennsylvania State University College of Medicine

“Evaluating the Cough Reflex in Pulmonary Fibrosis: Comparison with Healthy Controls”
Name: Dimmock, Anne
Institution: The Pennsylvania State University College of Medicine

“GLPG1690, a potential new treatment in idiopathic pulmonary fibrosis: design of the first-in-patient clinical trial”
Name: Fieuw, Ann
Institution: Galapagos

“PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients”
Name: Gorina, Eduard
Institution: FibroGen, Inc.

“Living With Idiopathic Pulmonary Fibrosis (L-IPF): Developing a Patient-Reported Symptom and Impact Questionnaire to Assess Health-Related Quality of Life in IPF”
Name: Graney, Bridget
Institution: National Jewish Health

“Diagnostic criteria, prevalence, and outcome of unclassifiable interstitial lung disease: A systematic review and meta-analysis.“
Name: Guler, Sabina
Institution: University of British Columbia

"FGF2 Overexpression Decreases Bleomycin-Induced Pulmonary Fibrosis”
Name: Guzy, Robert
Institution: The University of Chicago

“De Novo Serine/Glycine Synthesis is Required for TGF-beta-Induced Collagen Protein Production in Lung Fibroblasts“
Name: Hamanaka, Robert
Institution: The University of Chicago

“The Cough 55 Initiative: A Quality Improvement Project to Improve Early Detection in Pulmonary Fibrosis.”
Name: Hamblin, Mark
Institution: The University of Kansas Medical Center

“Endobronchial Optical Coherence Tomography for Low-Risk Microscopic Assessment and Diagnosis of UIP/IPF”
Name: Hariri, Lida
Institution: Massachusetts General Hospital (The General Hospital Corp.)

“Clinical features and outcomes associated with telomere pathway mutations in Familial Interstitial Pneumonia”
Name: Hewlett, Justin
Institution: Vanderbilt University Medical Center (VUMC)

“Predictors of physical activity in fibrotic interstitial lung disease”
Name: Hur, Seo Am
Institution: University of British Columbia

“Monocyte-derived alveolar macrophages are crucial for mediating lung fibrosis following asbestos exposure”
Name: Jablonski, Renea
Institution: Northwestern University - Chicago Campus

“Patient Perceptions of the Adequacy of Supplemental Oxygen Therapy: Results of the American Thoracic Society Nursing Assembly Oxygen Working Group Survey”
Name: Jacobs, Susan
Institution: Stanford University

“RXFP1 expression is regulated by miR-144-3p in Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis”
Name: Kass, Daniel
Institution: University of Pittsburgh

“Prevalence and Characteristics of Lung Cancer Amongst Patients with Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis”
Name: Kass, Daniel
Institution: University of Pittsburgh

“Pirfenidone and Patient Reported Outcomes in Idiopathic Pulmonary Fibrosis”
Name: Kay, Shannon
Institution: University of Michigan

“Enhanced expression of Phosphorylated JNK 1/2 in pulmonary fibroblast from patients with idiopathic pulmonary fibrosis (IPF) induces procollagen 1 synthesis”
Name: Khalil, Nasreen
Institution: University of British Columbia

“Associations of a Composite Physiologic Index with Quantitative Scores from Texture Features on HRCT images in Subjects with Idiopathic Pulmonary Fibrosis”
Name: Kim, Grace Hyun
Institution: The Regents of the University of California, Los Angeles

“Targeting HIF-1/PDK1 axis by Dichloroacetate (DCA) suppresses bleomycin-induced pulmonary fibrosis”
Name: Kim, Jung-whan
Institution: The University of Texas at Dallas

“The natural history of early interstitial changes in family members of patients with Familial Interstitial Pneumonia”
Name: Kropski, Jonathan
Institution: Vanderbilt University Medical Center

“Effect of nintedanib on disease progression: results from a Phase IIIb trial in patients with idiopathic pulmonary fibrosis (IPF)”
Name: Lancaster, Lisa
Institution: Vanderbilt University Medical Center

“Resolution of Pulmonary Fibrosis in a Rodent Model with a Novel Peptide Drug Delivered by Nebulization”
Name: Lento, Gina
Institution: Lung Therapeutics, Inc.

“Composite physiologic index (CPI) categorization and Gender Age Physiology (GAP) stage correlation and differentiation of patient-reported health-related quality of life in patients with idiopathic pulmonary fibrosis (IPF)”
Name: Leonard, Thomas
Institution: Boehringer Ingelheim Pharmaceuticals, Inc.

“High-dimensional single -cell mass cytometry (CyTOF) analysis of peripheral blood mononuclear cells (PBMCs) from IPF patients Enter a title here, then press Save.”
Name: Li, Qin
Institution: Yale University, School of Medicine

“Equipment, access and worry about running short of oxygen: Key concerns in the American Thoracic Society (ATS) Oxygen Working Group Patient Supplemental Oxygen Survey
Name: Lindell, Kathleen
Institution: University of Pittsburgh

“Therapeutic pamrevlumab (FG-3019) is more effective than pirfenidone or nintedanib in a mouse radiation-induced lung fibrosis model”
Name: Lipson, Kenneth
Institution: FibroGen, Inc.

“Incorporating Learner Data into Follow-up Education to Facilitate Peer-to-Peer Learning”
Name: LoPresti, Michael
Institution: Global Academy for Medical Education

“Frailty as an Outcome Measure in Idiopathic Pulmonary Fibrosis Patients”
Name: Luckhardt, Tracy
Institution: University of Alabama at Birmingham

“Regulation of Toll-Interacting Protein (TOLLIP) Expression by TOLLIP 3’UTR miRNA Polymorphisms in Human Peripheral Blood Monocyte Cells”
Name: Ma, Shwu-Fan
Institution: The University of Chicago

“Differences in Patient and Physician Viewpoints of the Management of Idiopathic Pulmonary Fibrosis (IPF)”
Name: Maher, Toby
Institution: Royal Marsden NHS Foundation Trust

“Systematic sampling of differentially affected microenvironments in Idiopathic Pulmonary Fibrosis lungs provides a timeline for functional and regulatory pathways in disease initiation and progression”
Name: Name: McDonough, John
Institution: Katholieke Universiteit Leuven

“Characterisation of novel LOXL2-selective inhibitors in in vitro and in vivo models of pulmonary fibrosis”
Name: Monk, Phillip
Institution: University of Southampton

“Targeted needs assessment for education of primary care physicians in interstitial lung disease”
Name: Morisset, Julie
Institution: Centre Hospitalier de l'Université de Montréal

“Effect of Pirfenidone on All-Cause Mortality (ACM) and Forced Vital Capacity (FVC) in Idiopathic Pulmonary Fibrosis (IPF) Patients With Low FVC and/or Low DLCO: Analysis of Pooled Data From ASCEND and CAPACITY”
Name: Nathan, Steven
Institution: Inova Fairfax Hospital

“Dose Modifications and Dose Intensity During Treatment With Pirfenidone”
Name: Nathan, Steven
Institution: Inova Fairfax Hospital

“Shorter Telomere Length is Associated with Poor Survival and Disease Progression in Interstitial Pneumonia with Autoimmune Features”
Name: Newton, Chad
Institution: UT Southwestern Medical Center

“Interleukin-11 is of central importance for lung fibroblast activation and drives pulmonary fibrosis”
Name: Ng, Benjamin
Institution: Duke- National University of Singapore

“Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials”
Name: Noth, Imre
Institution: The University of Chicago

“Genome-wide Association Study of Survival in Patients with Idiopathic Pulmonary Fibrosis”
Name: Oldham, Justin
Institution: The Regents of the University of California (University of California Davis)

“AN OBSERVATIONAL STUDY TO BETTER UNDERSTAND THE ADHERENCE AND USE OF HOME-BASED DIGITAL DEVICES TO MEASURE DISEASE-RELEVANT OUTCOMES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AND TO ASSESS FEASIBILITY FOR FUTURE STUDIES”
Name: Paula, Belloni
Institution: Genentech/Roche

“Unravelling the Mode of Action of Pulsed Inhaled Nitric Oxide in Severe IPF Using Functional Respiratory Imaging (FRI).”
Name: Quinn, Deborah
Institution: Bellerophon Therapeutics

“Improvement in forced vital capacity (FVC) with nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from the INPULSIS trials”
Name: Richeldi, Luca
Institution: Università Cattolica del Sacro Cuore (Catholic University of the Sacred Heart)

“IPF lung fibroblasts have a senescent phenotype”
Name: Rojas, Mauricio
Institution: University of Pittsburgh

“Role of HDAC8 in Pulmonary Fibrosis”
Name: Saito, Shigeki
Institution: Tulane University Health Sciences Center

“HP and IPF patients with similar radiologic phenotype experience similar outcomes”
Name: Salisbury, Margaret
Institution: University of Michigan Health System

“Characteristics of patients with idiopathic pulmonary fibrosis (IPF) receiving approved anti-fibrotic therapies in the US”
Name: Salisbury, Margaret
Institution: University of Michigan

“Chaperone Mediated Autophagy, a Critical Modulator of Pulmonary Health and Fibrosis.”
Name: Sanchez, Cecilia
Institution: Tulane University Health Sciences Center

“A role for Tensin 1 in myofibroblast differentiation and extracellular matrix formation”
Name: Sandbo, Nathan
Institution: University of Wisconsin-Madison

“Integrated discovery screens identify a novel therapeutic target for fibrosis”
Name: Schäfer, Sebastian
Institution: Duke- National University of Singapore

“Design of a randomized placebo-controlled Phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease (PF-ILD)”
Name: Schlenker-Herceg, Rozsa
Institution: Boehringer Ingelheim Pharma GmbH & Co. KG

“microRNAs in BAL fluid of patients with idiopathic pulmonary fibrosis”
Name: Schupp, Jonas
Institution: Yale University, School of Medicine

“Events leading to Idiopathic Pulmonary Fibrosis in administrative data”
Name: Shojaee, Abbas
Institution: Yale University, School of Medicine

“Engineered in vitro fibroblastic foci (FF) model of Idiopathic Pulmonary Fibrosis (IPF)”
Name: Sundarakrishnan, Aswin
Institution: Tufts University Medford Campus

“Stainless computed histopathology of bleomycin-induced pulmonary fibrosis by Fourier transform infrared technique”
Name: Suryadevara, Vidyani
Institution: University of Illinois at Chicago

“Discovery of a Small Molecule Inhibitor of the Wnt pathway (SM04646) Delivered as an Inhaled Aerosol for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)”
Name: Tam, Betty
Institution: Samumed

“Acetaminophen and the Extracellular Matrix in Idiopathic Pulmonary Fibrosis”
Name: Tran, Luc
Institution: George Mason University

“Significant Improvement in Refractory Chronic Cough with Inhaled PA101 (a Novel Formulation of Cromolyn Sodium) in Idiopathic Pulmonary Fibrosis Patients: Results from Phase 2 Trial”
Name: Tutuncu, Ahmet
Institution: Patara Pharma

“Utilization of Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: An Analysis of U.S. Claims Data’
Name: Viscidi, Emma
Institution: Biogen Inc.

“Spatio-temporal analysis of outcome predictive gene expression signatures in idiopathic pulmonary fibrosis”
Name: Vukmirovic, Milica
Institution: Yale University, School of Medicine

“Underutilization of lung transplant referral among patients with newly diagnosed idiopathic pulmonary fibrosis (IPF)”
Name: Whelan, Timothy
Institution: Medical University of South Carolina

“Thyromimetic Sobetirome (GC-1) Attenuates Bleomycin Induced Pulmonary Fibrosis”
Name: Yu, Guoying
Institution: Yale University

“NEURO-IMMUNE MECHANISMS AND PULMONARY FIBROSIS”
Name: Yu, Jerry
Institution: University of Louisville Research Foundation, Inc.

“The Role of Palliative Care and End-of-Life Discussions in Patients with Idiopathic Pulmonary Fibrosis”
Name: Zou, Richard
Institution: UPMC